Mesothelioma
Information
- Disease name
- Mesothelioma
- Disease ID
- Description
Disease area statistics
Chromosome band
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT03063450 | Active, not recruiting | Phase 3 | CheckpOiNt Blockade For Inhibition of Relapsed Mesothelioma | March 28, 2017 | February 2023 |
| NCT02784171 | Active, not recruiting | Phase 2/Phase 3 | Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma | November 11, 2016 | June 30, 2024 |
| NCT05451849 | Active, not recruiting | Phase 1/Phase 2 | A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer | June 21, 2022 | October 30, 2028 |
| NCT05311618 | Active, not recruiting | Phase 1 | Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors | May 11, 2022 | June 2025 |
| NCT00715611 | Active, not recruiting | Phase 2 | Pleurectomy/Decortication (Neo) Adjuvant Chemotherapy and Intensity Modulated Radiation Therapy to the Pleura in Patients With Locally Advanced Malignant Pleural Mesothelioma | October 11, 2008 | July 2025 |
| NCT04913337 | Active, not recruiting | Phase 1/Phase 2 | Study of NGM707 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies | June 9, 2021 | July 2025 |
| NCT04375267 | Active, not recruiting | Phase 1 | 177Lu-DOTA-TATE and Olaparib in Somatostatin Receptor Positive Tumours | April 23, 2020 | June 30, 2024 |
| NCT04334759 | Active, not recruiting | Phase 3 | DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma | February 18, 2021 | December 2025 |
| NCT04300244 | Active, not recruiting | Phase 2 | Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant Mesothelioma | May 4, 2020 | March 15, 2027 |
| NCT04272034 | Active, not recruiting | Phase 1 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors | March 26, 2021 | June 20, 2026 |
| NCT04242199 | Active, not recruiting | Phase 1 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors | September 4, 2020 | October 31, 2025 |
| NCT04234113 | Active, not recruiting | Phase 1 | Study of SO-C101 and SO-C101 in Combination With Pembro in Adult Patients With Advanced/Metastatic Solid Tumors | June 13, 2019 | November 2024 |
| NCT04040231 | Active, not recruiting | Phase 1 | Using a Targeted Cancer Vaccine (Galinpepimut-S) With Immunotherapy (Nivolumab) in Mesothelioma | July 24, 2019 | July 2024 |
| NCT03983954 | Active, not recruiting | Phase 1 | Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumors | October 10, 2019 | October 1, 2026 |
| NCT03918252 | Active, not recruiting | Phase 2 | Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma | October 2, 2019 | June 2026 |
| NCT03907852 | Active, not recruiting | Phase 1/Phase 2 | Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer | April 15, 2019 | November 2, 2028 |
| NCT03867578 | Active, not recruiting | N/A | Magnetic Resonance Imaging for Detection of Peritoneal Mesothelioma | October 10, 2018 | January 22, 2025 |
| NCT02414269 | Active, not recruiting | Phase 1/Phase 2 | Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin | May 2015 | April 30, 2025 |
| NCT02611037 | Active, not recruiting | Phase 2 | Transarterial Chemoperfusion: Cisplatin, Methotrexate, Gemcitabine for Unresectable Pleural Mesothelioma | March 4, 2016 | December 2024 |
| NCT00040625 | Approved for marketing | ALIMTA (Pemetrexed) Alone or in Combination With Cisplatin for Patients With Malignant Mesothelioma. | |||
| NCT03610360 | Completed | Phase 2/Phase 3 | DENdritic Cell Immunotherapy for Mesothelioma | June 21, 2018 | June 30, 2022 |
| NCT02467426 | Completed | Isolated Thoracic Perfusion (ITP-F) for MPM | September 2009 | May 2015 | |
| NCT00651456 | Completed | Phase 2/Phase 3 | Mesothelioma Avastin Plus Pemetrexed-cisplatin Study | February 2008 | September 2016 |
| NCT05041062 | Completed | Phase 2 | A Study of Immunotherapy Drugs Nivolumab and Ipilimumab in Patients w/Resectable Malignant Peritoneal Mesothelioma | December 1, 2021 | April 13, 2023 |
| NCT02798536 | Completed | Phase 1 | Mesothelin-Targeted Immunotoxin LMB-100 in People With Malignant Mesothelioma | July 27, 2016 | April 21, 2022 |
| NCT02948413 | Completed | Influence of Psychosocial Distress and Lifetime Trauma Exposure on Traumatic Stress Among Oncology Patients on Clinical Trials | November 10, 2016 | May 22, 2020 | |
| NCT00325494 | Completed | Phase 1 | A Study of MORAb-009 in Subjects With Pancreatic Cancer, Mesothelioma, or Certain Types of Ovarian or Lung Cancer | May 2006 | September 2008 |
| NCT00402766 | Completed | Phase 1 | Cisplatin, Pemetrexed, and Imatinib Mesylate in Malignant Mesothelioma | August 2006 | February 2014 |
| NCT00407459 | Completed | Phase 2 | Phase II Study of Bevacizumab, Pemetrexed and Carboplatin as First-Line Therapy in Malignant Pleural Mesothelioma | September 2007 | November 2010 |
| NCT00423254 | Completed | Phase 1 | Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer. | February 2007 | November 2009 |
| NCT00469196 | Completed | Phase 2 | Tomotherapy Treatment for Mesothelioma | October 2006 | May 2015 |
| NCT00535951 | Completed | Phase 1 | Pharmacokinetic, Safety, and Efficacy Effects of Oral LBH589 on Dextromethorphan in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer or Malignant Pleural Mesothelioma | November 2007 | |
| NCT00703638 | Completed | Phase 1 | Sorafenib, Pemetrexed, and Cisplatin in Treating Patients With Advanced Solid Tumors | May 2008 | November 2010 |
| NCT03538028 | Completed | Phase 1 | A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies | June 18, 2018 | October 7, 2020 |
| NCT02592551 | Completed | Phase 2 | MEDI4736 Or MEDI4736 + Tremelimumab In Surgically Resectable Malignant Pleural Mesothelioma | May 11, 2016 | September 1, 2022 |
| NCT04537715 | Completed | Phase 1 | Study to Describe the Interaction Between Tazemetostat and Itraconazole and Between Tazemetostat and Rifampin in Participants With Advanced Cancer | April 23, 2020 | April 3, 2023 |
| NCT00787410 | Completed | Phase 2 | An Open-label, Phase II Trial of ZD1839 (IRESSA) in Patients With Malignant Mesothelioma | September 2003 | April 2008 |
| NCT04481672 | Completed | Phase 1 | Intravenous Magnesium in Patients Receiving Cisplatin | July 30, 2021 | December 30, 2021 |
| NCT00859469 | Completed | Phase 2 | Eloxatin® Plus Gemcitabine Chemotherapy for Mesothelioma | April 2004 | March 2013 |
| NCT02610140 | Completed | Phase 2 | Phase II Anetumab Ravtansine as 2nd Line Treatment for Malignant Pleural Mesothelioma (MPM) | December 3, 2015 | September 6, 2019 |
| NCT00128102 | Completed | Phase 3 | Suberoylanilide Hydroxamic Acid (Vorinostat, MK-0683) Versus Placebo in Advanced Malignant Pleural Mesothelioma (MK-0683-014) | June 30, 2005 | November 21, 2011 |
| NCT01119664 | Completed | Phase 1 | Combination Gene Transfer and Chemotherapy | April 27, 2010 | March 17, 2017 |
| NCT01134146 | Completed | Phase 1 | Radical Pleurectomy/Decortication (PD) and Intensity Modulated Radiotherapy (IMRT) | May 27, 2010 | July 9, 2017 |
| NCT01135849 | Completed | B-Receptor Signaling in Cardiomyopathy | November 2008 | October 2010 | |
| NCT04316689 | Completed | Phase 1 | First-in-human Study of S-588210 (S-488210+S-488211) | July 30, 2019 | September 22, 2021 |
| NCT01204203 | Completed | Phase 2 | Pilot Study of Bisphosphonate Therapy (Zoledronic Acid) in Patients With Malignant Mesothelioma (UAB 0901) | June 2009 | April 2016 |
| NCT00316225 | Completed | Phase 2 | Study of Pemetrexed in Mesothelioma and Lung Cancer Patients With Fluid Around the Lungs or Abdomen | December 2006 | March 2009 |
| NCT01356251 | Completed | N/A | Psychosocial Needs and Exploration of Online Support for Patients With Mesothelioma | May 2011 | February 6, 2023 |
| NCT01362790 | Completed | Phase 1/Phase 2 | SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma | May 11, 2011 | August 7, 2017 |
| NCT01401907 | Completed | N/A | Early Palliative Care in Advanced Lung and Gastrointestinal Malignancies | May 2011 | December 2019 |
| NCT00137826 | Completed | Phase 2 | Bevacizumab (Avastin) and Erlotinib (Tarceva) in Previously Treated Mesothelioma | February 2004 | July 2009 |
| NCT00188890 | Completed | Early Diagnosis of Lung Cancer and Mesothelioma in Prior Asbestos Workers | March 2005 | July 3, 2019 | |
| NCT01521325 | Completed | Phase 1 | A Single-Dose Pilot Study of Radiolabeled Amatuximab (MORAb-009) in Mesothelin Over Expressing Cancers | September 2011 | March 2013 |
| NCT00190762 | Completed | Phase 3 | A Study Comparing Pemetrexed Plus Best Supportive Care Versus Best Supportive Care Alone in the Treatment of Mesothelioma | October 2001 | November 2005 |
| NCT04153565 | Completed | Phase 1 | A Study of Pembrolizumab in Combination With Cisplatin and Pemetrexed in Advanced Malignant Pleural Mesothelioma (MPM) (MK-3475-A17) | December 9, 2019 | September 21, 2022 |
| NCT01590472 | Completed | Do Your Genes Put You at a Higher Risk of Developing Mesothelioma | June 2011 | December 2015 | |
| NCT04088786 | Completed | Phase 1 | Phase I Trial HIPEC With Nal-irinotecan | October 22, 2019 | April 14, 2022 |
| NCT04056026 | Completed | Early Phase 1 | A Single Dose FMT Infusion as an Adjunct to Keytruda for Metastatic Mesothelioma | September 18, 2018 | December 18, 2018 |
| NCT03531840 | Completed | Phase 2 | Olaparib in People With Malignant Mesothelioma | July 11, 2018 | October 21, 2020 |
| NCT00295503 | Completed | Phase 2 | Cisplatin, Pemetrexed and Bevacizumab for Untreated Malignant Mesothelioma | February 2006 | August 2010 |
| NCT01776385 | Completed | N/A | The ISET (Isolation by Size of Epithelial Tumor Cells) and the CellSearch Methods in Malignant Pleural Mesothelioma | February 2012 | March 2018 |
| NCT03517488 | Completed | Phase 1 | A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors | July 10, 2018 | September 6, 2022 |
| NCT03207347 | Completed | Phase 2 | A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001) | August 13, 2018 | August 30, 2022 |
| NCT00061477 | Completed | Phase 2 | Pemetrexed Plus Gemcitabine as Front-Line Chemotherapy for Patients With Malignant Pleural or Peritoneal Mesothelioma | December 2002 | September 2006 |
| NCT01997190 | Completed | Phase 1 | Intrapleural AdV-tk Therapy in Patients With Malignant Pleural Effusion | October 2013 | February 2018 |
| NCT00004547 | Completed | Phase 2 | Treatment of Peritoneal Cancer With Surgery, Perfused Heated Cisplatin and Chemotherapy | January 2000 | August 2009 |
| NCT02029105 | Completed | Serum Biomarkers in Diagnosis of Mesothelioma | January 2004 | October 2013 | |
| NCT02709512 | Completed | Phase 2/Phase 3 | Ph 2/3 Study in Subjects With MPM to Assess ADI-PEG 20 With Pemetrexed and Cisplatin | August 1, 2017 | August 15, 2022 |
| NCT03656549 | Completed | Phase 2 | Dose Individualization of Pemetrexed - IMPROVE-I | February 1, 2019 | December 29, 2023 |
| NCT02071862 | Completed | Phase 1 | Study of the Glutaminase Inhibitor CB-839 in Solid Tumors | February 2014 | March 2019 |
| NCT00101283 | Completed | Phase 2 | Pemetrexed Plus Gemcitabine or Carboplatin for Patients With Advanced Malignant Pleural Mesothelioma | February 23, 2006 | May 2011 |
| NCT02078700 | Completed | Phase 2 | Feasibility of an Early Palliative Care Intervention for Metastatic Cancer Patients. A Phase 2 Study. | July 2013 | December 2014 |
| NCT02139904 | Completed | Phase 2 | Vinorelbine in Mesothelioma | March 1, 2016 | March 17, 2021 |
| NCT02293005 | Completed | Phase 2 | Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma | May 20, 2015 | July 6, 2021 |
| NCT03655834 | Completed | Phase 4 | Dose Individualization of Pemetrexed - IMPROVE-III | February 1, 2019 | August 1, 2021 |
| NCT03652077 | Completed | Phase 1 | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | September 24, 2018 | August 18, 2021 |
| NCT02716272 | Completed | Phase 2 | Nivolumab Monotherapy or Nivolumab Plus Ipilimumab, for Unresectable Malignant Pleural Mesothelioma (MPM) Patients | March 24, 2016 | June 22, 2019 |
| NCT03023319 | Completed | Phase 1 | Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors | December 10, 2019 | May 10, 2022 |
| NCT02958683 | Completed | Chest Wall Motion Analysis in Disease | July 2011 | July 31, 2015 | |
| NCT02860286 | Completed | Phase 2 | Study of the EZH2 Inhibitor Tazemetostat in Malignant Mesothelioma | July 2016 | May 2019 |
| NCT02899195 | Completed | Phase 2 | Phase II MEDI4736 in Combination With Chemotherapy for First-Line Treatment of Unresectable Mesothelioma | June 13, 2017 | June 29, 2023 |
| NCT02899299 | Completed | Phase 3 | Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients | November 29, 2016 | April 28, 2023 |
| NCT02903914 | Completed | Phase 1/Phase 2 | Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors | September 14, 2016 | August 15, 2022 |
| NCT02875548 | Enrolling by invitation | Phase 1/Phase 2 | A Study to Assess the Long-term Safety of Tazemetostat | August 30, 2016 | November 3, 2025 |
| NCT01385722 | Enrolling by invitation | Molecular Analysis of Thoracic Malignancies | August 2011 | June 2031 | |
| NCT06196294 | Not yet recruiting | Phase 1 | GPC3/Mesothelin-CAR-γδT Cells Against Cancers | January 10, 2024 | December 30, 2033 |
| NCT04985357 | Not yet recruiting | Defining the Clinical Potential of Mass Response as a Biomarker for Patient Tumor Sensitivity to Drugs | June 2024 | May 2030 | |
| NCT05932199 | Not yet recruiting | Phase 1/Phase 2 | Neoadjuvant Durvalumab and Tremelimumab With and Without Chemotherapy for Mesothelioma | January 15, 2024 | May 31, 2028 |
| NCT05819580 | Not yet recruiting | Studying the Clinical Trial Experiences of Patients With Mesothelioma | May 2024 | May 2026 | |
| NCT06444815 | Not yet recruiting | Phase 1 | A Study of VET3-TGI in Patients With Solid Tumors | August 1, 2024 | December 31, 2027 |
| NCT06452160 | Recruiting | Phase 1 | A Study of BGC515 Capsules in Subjects With Advanced Solid Tumors | June 2024 | December 2027 |
| NCT01851395 | Recruiting | Rapid Autopsy and Procurement of Cancer Tissue | December 30, 2013 | ||
| NCT01950572 | Recruiting | Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma | September 9, 2013 | ||
| NCT02012699 | Recruiting | Integrated Cancer Repository for Cancer Research | November 1, 2013 | December 2099 | |
| NCT02073500 | Recruiting | Peritoneal Surface Malignancies - Characterization, Models and Treatment Strategies | September 2009 | August 2027 | |
| NCT02611024 | Recruiting | Phase 1/Phase 2 | Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors | May 6, 2016 | March 2026 |
| NCT02613299 | Recruiting | Surgery for Mesothelioma After Radiation Therapy "SMART" for Resectable Malignant Pleural Mesothelioma | November 2015 | December 2024 | |
| NCT02613312 | Recruiting | Chemotherapy Followed by Surgery and Neoadjuvant Hemothoracic Intensity Modified Radiation Therapy (IMRT) for Patients With Malignant Pleural Mesothelioma | March 18, 2016 | December 2024 | |
| NCT02628067 | Recruiting | Phase 2 | Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) | December 18, 2015 | May 4, 2027 |
| NCT02648763 | Recruiting | Staging Procedures to Diagnose Malignant Pleural Mesothelioma | March 14, 2016 | December 2024 | |
| NCT02748798 | Recruiting | Early Phase 1 | Developing Optimal Parameters for Hyperpolarized Noble Gas and Inert Fluorinated Gas MRI of Lung Disorders | November 10, 2020 | December 22, 2023 |
| NCT03556228 | Recruiting | Phase 1 | Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma | June 8, 2018 | June 2026 |
| NCT03683680 | Recruiting | N/A | Prospectively Collected Pleural Biopsies for Validation of Malignant Pleural Mesothelioma Prognostic Biomarkers | October 31, 2018 | October 1, 2025 |
| NCT03830229 | Recruiting | Long Term Follow-up of Mesothelioma Patients and Their Family Members With Germline Mutations in BAP1 and Other Genes | March 13, 2019 | July 5, 2027 | |
| NCT03881488 | Recruiting | Phase 1 | Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies | May 17, 2019 | April 2025 |
| NCT03935893 | Recruiting | Phase 2 | Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers | December 3, 2019 | June 30, 2037 |
| NCT04028479 | Recruiting | The Registry of Oncology Outcomes Associated With Testing and Treatment | May 5, 2021 | October 1, 2031 | |
| NCT04431024 | Recruiting | Prospective Evaluation of High Resolution Dual Energy Computed Tomographic Imaging, Noninvasive (Liquid) Biopsies, and Minimally Invasive Surgical Surveillance for Early Detection of Mesotheliomas in Patients With BAP1 Tumor Predisposition Syndrome | March 30, 2021 | June 30, 2038 | |
| NCT04515836 | Recruiting | Phase 2 | Olaparib in Patients With HRD Malignant Mesothelioma | February 19, 2021 | October 15, 2025 |
| NCT04631731 | Recruiting | Phase 1/Phase 2 | Risk Factors of Immune-ChEckpoint Inhibitors MEdiated Liver, Gastrointestinal, Endocrine and Skin Toxicity | December 15, 2020 | December 10, 2025 |
| NCT04665206 | Recruiting | Phase 1/Phase 2 | Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors Enriched for Tumors With NF2 or mNF2 Gene Mutations | March 24, 2021 | June 2, 2027 |
| NCT04792463 | Recruiting | Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome | March 3, 2015 | July 1, 2026 | |
| NCT04802876 | Recruiting | Phase 2 | Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients With PD1-high mRNA Expressing Tumors | April 12, 2021 | March 31, 2027 |
| NCT04857372 | Recruiting | Phase 1 | A Phase I Study of IAG933 in Patients With Advanced Mesothelioma and Other Solid Tumors | October 21, 2021 | October 6, 2025 |
| NCT04940637 | Recruiting | Phase 2 | UNITO-001- Study in HRR/PDL1 Positive MPM/NSCLC | December 23, 2020 | June 30, 2025 |
| NCT04981119 | Recruiting | Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing | October 29, 2021 | December 2026 | |
| NCT05070247 | Recruiting | Phase 1/Phase 2 | A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors | April 14, 2022 | August 11, 2026 |
| NCT05215574 | Recruiting | Phase 1 | Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors | March 31, 2022 | March 2026 |
| NCT05238883 | Recruiting | Phase 1 | A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors | March 10, 2022 | December 2026 |
| NCT05245500 | Recruiting | Phase 1/Phase 2 | Phase 1/2 Study of MRTX1719 in Solid Tumors With MTAP Deletion | June 2, 2022 | April 30, 2026 |
| NCT05278975 | Recruiting | Phase 1/Phase 2 | Study of RSO-021 in Patients With Malignant Pleural Effusion Due to Advanced/Metastatic Solid Tumors Including Mesothelioma | March 31, 2022 | April 1, 2025 |
| NCT05415098 | Recruiting | Phase 1 | Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas | September 30, 2022 | September 30, 2025 |
| NCT05461430 | Recruiting | Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx) | July 15, 2022 | July 2026 | |
| NCT05544929 | Recruiting | Phase 1 | A Study of Safety and Efficacy of KFA115 Alone and in Combination With Pembrolizumab in Patients With Select Advanced Cancers | October 26, 2022 | February 20, 2026 |
| NCT05571839 | Recruiting | Phase 1 | A Study of SGN-BB228 in Advanced Melanoma and Other Solid Tumors | January 3, 2023 | September 30, 2028 |
| NCT05579366 | Recruiting | Phase 1/Phase 2 | PRO1184 for Advanced Solid Tumors | December 7, 2022 | April 2026 |
| NCT05627960 | Recruiting | Phase 1 | First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies | February 14, 2022 | November 2026 |
| NCT05730816 | Recruiting | Phase 2 | MAGIC AKI: Magnesium for the Prevention of HIOC-Associated AKI | April 4, 2023 | January 1, 2028 |
| NCT05960773 | Recruiting | Phase 2 | Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma | January 31, 2024 | December 1, 2026 |
| NCT06010277 | Recruiting | Phase 4 | Folinic Acid for Prevention of Pemetrexed-induced Toxicity | February 6, 2023 | January 2024 |
| NCT06034860 | Recruiting | Phase 1 | Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types | November 1, 2023 | October 2026 |
| NCT06051695 | Recruiting | Phase 1/Phase 2 | A Study to Evaluate the Safety and Efficacy of A2B694, a Logic-gated CAR T, in Subjects With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression | April 3, 2024 | June 2029 |
| NCT06057935 | Recruiting | Phase 2 | A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma | September 21, 2023 | September 21, 2028 |
| NCT04115254 | Suspended | N/A | Stereotactic Magnetic Resonance Guided Radiation Therapy | October 22, 2019 | June 2024 |
| NCT03075527 | Suspended | Phase 2 | A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural Mesothelioma | April 10, 2017 | September 30, 2024 |
| NCT01627795 | Suspended | Phase 1/Phase 2 | Safety and Efficacy of Oshadi D and Oshadi R for Malignant Mesothelioma Treatment | December 2016 | December 2018 |
| NCT02464904 | Terminated | N/A | Intrapleural Cryotherapy for Malignant Pleural Mesothelioma | July 2015 | February 26, 2021 |
| NCT00895648 | Terminated | Phase 2 | Pemetrexed (ALIMTA) Plus Cisplatin Followed by Surgery and Radiation Therapy for Mesothelioma | January 2009 | October 2012 |
| NCT03644550 | Terminated | Phase 2 | Anti-Mesothelin Immunotoxin LMB-100 Followed by Pembrolizumab in Malignant Mesothelioma | December 4, 2018 | November 2, 2020 |
| NCT01604005 | Terminated | Phase 3 | PIT: Prophylactic Irradiation of Tracts in Patients With Malignant Pleural Mesothelioma | July 2012 | April 5, 2017 |
| NCT03655821 | Terminated | Phase 4 | Dose Individualization of Pemetrexed - IMPROVE-II | February 1, 2019 | May 11, 2021 |
| NCT02385812 | Terminated | Phase 2 | Screening of Alberta Asbestos Exposed Workers for Lung Cancer and Mesothelioma | January 1, 2015 | April 1, 2022 |
| NCT02062632 | Terminated | Phase 2 | Doxepin Hydrochloride in Treating Esophageal Pain in Patients With Thoracic Cancer Receiving Radiation Therapy to the Thorax With or Without Chemotherapy | April 14, 2014 | November 6, 2017 |
| NCT00637624 | Terminated | N/A | N-AcetylCysteine vs. Placebo to Prevent Neurotoxicity Induced by Platinum Containing Chemotherapy | March 2008 | July 2017 |
| NCT01624090 | Terminated | Phase 2 | Mithramycin for Lung, Esophagus, and Other Chest Cancers | September 6, 2012 | September 27, 2019 |
| NCT01413451 | Terminated | Early Phase 1 | Amatuximab for High Mesothelin Cancers | July 12, 2011 | November 15, 2013 |
| NCT01583686 | Terminated | Phase 1/Phase 2 | CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer | May 4, 2012 | December 17, 2018 |
| NCT04301011 | Terminated | Phase 1/Phase 2 | Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors | June 2, 2020 | January 23, 2023 |
| NCT00604461 | Terminated | Phase 1/Phase 2 | Carboplatin, Bevacizumab and Pemetrexed in the First-Line Treatment of Patients With Malignant Pleural Mesothelioma (MPM) | October 2007 | January 2011 |
| NCT00597116 | Terminated | Phase 2 | An Efficacy and Safety Study With Vandetanib to Treat Inoperable or Relapsed Malignant Mesothelioma | December 2007 | January 2010 |
| NCT00094978 | Terminated | Phase 1 | Depsipeptide/Flavopiridol Infusion for Cancers of the Lungs, Esophagus, Pleura, Thymus or Mediastinum | October 25, 2004 | May 20, 2013 |
| NCT01907100 | Terminated | Phase 2/Phase 3 | Nintedanib (BIBF 1120) in Mesothelioma | September 19, 2013 | August 31, 2018 |
| NCT01188486 | Terminated | N/A | Pulmonary Interstitial Lymphography in Early Stage Lung Cancer | August 2010 | April 30, 2017 |
| NCT02859415 | Terminated | Phase 1/Phase 2 | Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary Metastases | August 8, 2019 | December 1, 2021 |
| NCT02838745 | Terminated | Phase 1 | Study of Cytoreductive Surgery and Hyperthermic Intraoperative Chemotherapy With Pemetrexed and Cisplatin for MPM | September 2016 | September 5, 2019 |
| NCT01445392 | Terminated | Phase 1 | SS1(dsFV)PE38 Plus Pemetrexed and Cisplatin to Treat Malignant Pleural Mesothelioma | November 14, 2007 | October 3, 2016 |
| NCT02688166 | Terminated | Cardiac MRI Biomarker Testing (GCC 1618) | February 1, 2018 | September 9, 2022 | |
| NCT03319537 | Terminated | Phase 1/Phase 2 | Pevonedistat Alone and in Combination With Chemotherapy in Patients With Mesothelioma | October 5, 2017 | June 5, 2023 |
| NCT03436732 | Terminated | Phase 1 | Mesothelin-Targeted Immunotoxin LMB-100 in Combination With SEL-110 in Subjects With Malignant Pleural or Peritoneal Mesothelioma | February 28, 2018 | April 30, 2019 |
| NCT02628535 | Terminated | Phase 1 | Safety Study of MGD009 in B7-H3-expressing Tumors | September 2015 | November 25, 2019 |
| NCT00748085 | Terminated | N/A | CryoSpray Ablation(tm)in Malignant Airway Disease to Determine Safety, and Tissue Effect in the Lung (ICE the MAD) | October 2008 | August 2009 |
| NCT03685591 | Terminated | Phase 1 | PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors | October 4, 2018 | March 30, 2022 |
| NCT04840615 | Terminated | Phase 1 | Intratumor Injection of Anti-Mesothelin Immunotoxin LMB-100 With Ipilimumab in Malignant Mesothelioma | June 11, 2021 | January 12, 2022 |
| NCT03560973 | Unknown status | Phase 2 | A Double Blind, Placebo Controlled, Randomized Phase II Study Evaluating Gemcitabine With or Without Ramucirumab , for II Line Treatment MPM | December 22, 2016 | December 22, 2020 |
| NCT04214015 | Unknown status | A Pilot Study to Explore the Role of Gut Flora in Metastatic Mesothelioma | March 2, 2020 | July 2023 | |
| NCT01569919 | Unknown status | Phase 2 | A Phase II Trial to Assess TroVax® Plus Chemotherapy in Patients With Malignant Pleural Mesothelioma | December 2012 | December 2014 |
| NCT01281800 | Unknown status | Phase 2 | Cisplatin With Alimta or Gemcitabine in Long Infusion for Mesothelioma | August 2008 | |
| NCT00996385 | Unknown status | Phase 2 | Velcade and Eloxatin for Patients With Malignant Pleural or Peritoneal Mesothelioma | September 2009 | September 2014 |
| NCT04450043 | Unknown status | N/A | The Transitions Project: Supporting Adults During the Shift From Cancer Treatment to Surveillance | August 1, 2020 | November 1, 2023 |
| NCT00794859 | Unknown status | Phase 2 | Sorafenib in Previously Treated Malignant Mesothelioma | October 2008 | |
| NCT04489862 | Unknown status | Early Phase 1 | αPD1-MSLN-CAR T Cells for the Treatment of MSLN-positive Advanced Solid Tumors | May 13, 2020 | December 2022 |
| NCT00551252 | Unknown status | Phase 2 | A Phase II Study of the Association of Glivec® Plus Gemzar® in Patients With Unresectable, Refractory, Malignant Mesothelioma | January 2008 | December 2009 |
| NCT02758587 | Unknown status | Phase 1/Phase 2 | Study of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Advanced Solid Malignancies (FAK-PD1) | July 4, 2017 | December 2021 |
| NCT03638206 | Unknown status | Phase 1/Phase 2 | Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies | March 1, 2018 | March 1, 2023 |
| NCT02395679 | Unknown status | Phase 1 | Dendritic Cells Loaded With Allogeneous Cell Lysate in Mesothelioma Patients | January 2015 | December 2016 |
| NCT02040272 | Unknown status | N/A | Mesothelioma and Radical Surgery 2 | May 2015 | September 2022 |
| NCT00454519 | Unknown status | Phase 2 | Surgery Plus Intraoperative Peritoneal Hyperthermic Chemotherapy (IPHC) to Treat Peritoneal Carcinomatosis | March 2007 | |
| NCT01912547 | Unknown status | Thromboelastography During Surgery for Malignant Pleural Mesothelioma | September 2013 | December 2015 | |
| NCT00629343 | Unknown status | Phase 1 | Phase I Dose-Escalation Study Of Azacitidine In Combination With Temozolomide | October 2007 | August 2014 |
| NCT01719068 | Unknown status | Early Detection of Lung Cancer and Mesothelioma in Workers Exposed to Asbestos | October 2012 | December 2014 | |
| NCT00685204 | Unknown status | Phase 2 | An Efficacy Study of Milataxel (TL139) Administered Orally for Malignant Mesothelioma | March 2008 | |
| NCT02511600 | Withdrawn | Phase 3 | Comparison of Progel Sealant to Standard of Care (SOC) for Patients Undergoing Decortication | December 2015 | |
| NCT02661100 | Withdrawn | Phase 1/Phase 2 | A Trial of CDX-1401 in Combination With Poly-ICLC and Pembrolizumab, in Previously Treated Advanced Solid Tumor Patients | January 2017 | July 2018 |
| NCT00785239 | Withdrawn | CryoSpray Ablation(tm)Thoracic Patient Registry | April 2009 | April 2009 | |
| NCT00668499 | Withdrawn | Phase 1/Phase 2 | A Study of VEGF-Antisense Oligonucleotide in Combination With Pemetrexed and Cisplatin for the Treatment of Advanced Malignant Mesothelioma | April 2008 | April 2011 |
| NCT04429204 | Withdrawn | N/A | Cryoablation for the Promotion of Local Tumor Infiltration in Patients With Mesothelioma | December 1, 2021 | December 1, 2023 |
| NCT06090318 | Withdrawn | Phase 1/Phase 2 | Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss | May 19, 2023 | May 30, 2023 |
- ICD10 preferred id (Insert disease from ICD10)
- D0002018
- ICD10 class code (Insert disease from ICD10)
- C45
- MeSH unique ID (MeSH (Medical Subject Headings))
- D008654